216 related articles for article (PubMed ID: 14998989)
1. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice.
Shen Q; Cline GW; Shulman GI; Leibowitz MD; Davies PJ
J Biol Chem; 2004 May; 279(19):19721-31. PubMed ID: 14998989
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
3. Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes.
Standaert ML; Kanoh Y; Sajan MP; Bandyopadhyay G; Farese RV
Endocrinology; 2002 May; 143(5):1705-16. PubMed ID: 11956152
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.
Jiang G; Dallas-Yang Q; Li Z; Szalkowski D; Liu F; Shen X; Wu M; Zhou G; Doebber T; Berger J; Moller DE; Zhang BB
Diabetes; 2002 Aug; 51(8):2412-9. PubMed ID: 12145152
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Cbl-associated protein/Cbl pathway in muscle and adipose tissues of two animal models of insulin resistance.
Thirone AC; Carvalheira JB; Hirata AE; Velloso LA; Saad MJ
Endocrinology; 2004 Jan; 145(1):281-93. PubMed ID: 14525909
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
7. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes.
Ishibashi KI; Imamura T; Sharma PM; Huang J; Ugi S; Olefsky JM
J Clin Invest; 2001 May; 107(9):1193-202. PubMed ID: 11342583
[TBL] [Abstract][Full Text] [Related]
8. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.
Kausch C; Krützfeldt J; Witke A; Rettig A; Bachmann O; Rett K; Matthaei S; Machicao F; Häring HU; Stumvoll M
Biochem Biophys Res Commun; 2001 Jan; 280(3):664-74. PubMed ID: 11162573
[TBL] [Abstract][Full Text] [Related]
9. Muscle fiber type-specific defects in insulin signal transduction to glucose transport in diabetic GK rats.
Song XM; Kawano Y; Krook A; Ryder JW; Efendic S; Roth RA; Wallberg-Henriksson H; Zierath JR
Diabetes; 1999 Mar; 48(3):664-70. PubMed ID: 10078575
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
Wu Y; Ouyang JP; Wu K; Wang SS; Wen CY; Xia ZY
Br J Pharmacol; 2005 Sep; 146(2):234-43. PubMed ID: 15997237
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.
Wang X; Hu Z; Hu J; Du J; Mitch WE
Endocrinology; 2006 Sep; 147(9):4160-8. PubMed ID: 16777975
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
Higashi Y; Holder K; Delafontaine P
J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation.
Kruszynska YT; Worrall DS; Ofrecio J; Frias JP; Macaraeg G; Olefsky JM
J Clin Endocrinol Metab; 2002 Jan; 87(1):226-34. PubMed ID: 11788651
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.
Goetze S; Kim S; Xi XP; Graf K; Yang DC; Fleck E; Meehan WP; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 2000 May; 35(5):749-57. PubMed ID: 10813377
[TBL] [Abstract][Full Text] [Related]
15. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
Dokken BB; Sloniger JA; Henriksen EJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
[TBL] [Abstract][Full Text] [Related]
16. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
[TBL] [Abstract][Full Text] [Related]
17. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice.
Shao J; Yamashita H; Qiao L; Friedman JE
J Endocrinol; 2000 Oct; 167(1):107-15. PubMed ID: 11018758
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Ogihara T; Asano T; Ando K; Chiba Y; Sekine N; Sakoda H; Anai M; Onishi Y; Fujishiro M; Ono H; Shojima N; Inukai K; Fukushima Y; Kikuchi M; Fujita T
Diabetes; 2001 Mar; 50(3):573-83. PubMed ID: 11246877
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.
Hu S; Yao J; Howe AA; Menke BM; Sivitz WI; Spector AA; Norris AW
Mol Endocrinol; 2012 Jun; 26(6):977-88. PubMed ID: 22474127
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle.
Oku A; Nawano M; Ueta K; Fujita T; Umebayashi I; Arakawa K; Kano-Ishihara T; Saito A; Anai M; Funaki M; Kikuchi M; Oka Y; Asano T
Am J Physiol Endocrinol Metab; 2001 May; 280(5):E816-24. PubMed ID: 11287365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
